

ACR ADVOCACY

Federal ADVOCACY



+\$2 billion in NIH funding

Medicare extended 365 look-back period protecting stable patients from step therapy



Hill briefing on prevalence of arthritis in the military

Bill to restrict use of prior authorization in house

Step therapy bills in House & Senate with 115 bipartisan co-sponsors

Pediatric Specialty Loan Repayment passes House; introduced in Senate



Estimated **15%** payment increase finalized for rheumatology, beginning in 2021.



FDA finalized ACR-approved pathway for interchangeable biosimilars

Protect Part B drug payments, in-office treatments briefing

Hill briefing on need to boost DXA reimbursement & risks related to osteoporosis and fractures

Bills boosting DXA reimbursement with 54 bipartisan co-sponsors

State ADVOCACY



26 states with step therapy protections

45 states with restrictions on PBMs

49 states with biosimilar substitution legislation

2019 BY THE NUMBERS

6 published op-eds & letters to the editor

meetings between federal legislative offices & ACR/ARP volunteers

228

93

news stories featuring ACR's advocacy positions

25 letters to payers

3,497,667 impressions of #Act4Arthritis

1,969

emails sent to Congress on rheumatology issues

- 1,546 federal emails sent through ACR
- 108 emails sent on state issues through ACR
- 315 emails sent through Simple Tasks